ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2231

Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis

Neil Accortt1, Jennifer Schenfeld2,3, Eunice Chang4, Elya Papoyan4 and Michael S. Broder4, 1Center for Observational Research, Amgen, Inc, Thousand Oaks, CA, 2Docs Global, Inc, North Wales, PA, 3Amgen Inc., Thousand Oaks, CA, 4Partnership for Health Analytic Research, LLC, Beverly Hills, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: etanercept, observation, outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Health Services Research - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of biologic treatment on HCU. The purpose of this study was to evaluate HCU before and after etanercept (ETN) initiation.

Methods: We conducted a retrospective cohort study using claims data. Adult RA patients newly exposed to ETN from January 1, 2010 through December 31, 2013 were included. Patients were required to have at least 1 inpatient or outpatient claim for RA (ICD-9-CM 714.0) in the primary position, and at least 1 ETN medication claim; the earliest ETN claim served as index date. Patients were excluded if they had exposure to a biologic DMARD or had a claim for psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile idiopathic arthritis. The proportion of days covered (PDC) was calculated and used as a measure of ETN compliance. The primary outcome was the change in HCU (both overall and RA-related) in the year before and after ETN initiation. McNemar’s test and paired t-test were used to determine statistical significance for dichotomous and continuous variables, respectively. To compare the HCU across ETN compliance groups, F-test and Chi-square test were used for categorical and continuous variables, respectively.

Results: We identified 6,737 ETN initiators. The mean age was 49.8 years and 77.3% were female. Frequency of medication use for oral corticosteroids, opioid analgesics, NSAIDS and NB-DMARDS decreased significantly from the pre-index to post-index period (Table 1). There was a significant decrease in overall outpatient services, ED visits and hospitalizations from the pre-index to post-index period (data not shown). In the post-index period, there was a statistically significant decrease in HCU factors with increasing ETN compliance (Table 2).

Conclusion: Health care utilization, including medication use, outpatient services and inpatient admissions decreased after ETN initiation. Patients who were the most compliant with their medication experienced significantly lower utilization than non-compliant patients. The reduction in HCU is consistent with a reduction in disease activity as shown in clinical trials of ETN.2 1.       Michet CJ, et al. Hospitalization Rates and Utilization Among Patients With Rheumatoid Arthritis: A Population-Based Study From 1987 to 2012 in Olmsted County, Minnesota. Mayo Clinic Proceedings. 2015;90:176–183.

2.       Moreland LW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Annals of internal medicine. 1999 Mar 16;130(6):478-86.


Disclosure: N. Accortt, Amgen, 3,Amgen, 1; J. Schenfeld, Docs Global, Inc., 3,Amgen, Inc., 5; E. Chang, Amgen, 3; E. Papoyan, None; M. S. Broder, Amgen, 3.

To cite this abstract in AMA style:

Accortt N, Schenfeld J, Chang E, Papoyan E, Broder MS. Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/change-in-health-care-utilization-after-etanercept-initiation-in-patients-with-rheumatoid-arthritis/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/change-in-health-care-utilization-after-etanercept-initiation-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.